| Drug Name | Moxifloxacin | 
							
								| Drug ID | BADD_D01501 | 
							
								| Description | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | 
							
								| Indications and Usage | For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye). | 
							
								| Marketing Status | approved; investigational | 
				
							
								| ATC Code | J01MA14; S01AE07 | 
							
								| DrugBank ID | DB00218 | 
							
								| KEGG ID | D08237 | 
							
								| MeSH ID | D000077266 | 
							
								| PubChem ID | 152946 | 
							
								| TTD Drug ID | D0ZV0Z | 
							
								| NDC Product Code | 65977-0038; 51407-321; 63629-8357; 0378-5430; 65862-840; 72189-321; 16714-643; 50090-6357; 55111-112; 70518-3713; 80425-0239; 50090-5833; 53002-2723; 68180-421; 61919-553; 72789-233; 60505-0582; 68180-422; 72189-334; 17478-519; 31722-845; 0904-6406; 12527-0517; 50090-3147 | 
							
								| UNII | U188XYD42P | 
							
								| Synonyms | Moxifloxacin | 1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | Octegra | Proflox | Moxifloxacin Hydrochloride | Avelox | Avalox | Izilox | Actira | BAY 12-8039 | BAY 12 8039 | BAY-12-8039 | BAY 128039 | BAY-128039 | BAY128039 |